SCHEMBL6920540

SCHEMBL6920540

COC(C)(C)c1nc2cc(-c3ccccn3)ccc2c(=O)n1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.47
TGFBR1 P36897 1/20 0.41
DHODH Q02127 1/20 0.39
METAP2 P50579 2/20 0.39
GABRG2 P18507 1/20 0.38
GABRB3 P28472 1/20 0.38
GABRA3 P34903 1/20 0.38
BRD4 O60885 2/20 0.37
PRMT5 O14744 2/20 0.36
WDR77 Q9BQA1 1/20 0.36
RET P07949 1/20 0.35
RIPK1 Q13546 1/20 0.35
RIPK3 Q9Y572 1/20 0.35
ALOX5AP P20292 1/20 0.35
PIK3CD O00329 1/20 0.35
PIK3CA P42336 1/20 0.35
PI4KA P42356 1/20 0.35
PIK3CG P48736 1/20 0.35
PI4KB Q9UBF8 1/20 0.35
AXL P30530 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12059114 0.80 CYP3A4 (0.49) CYP3A4TGFBR1DHODHMETAP2GABRG2
SCHEMBL6921132 0.79 CYP3A4 (0.46) CYP3A4TGFBR1DHODHMETAP2GABRG2
SCHEMBL6921917 0.77 USP2 (0.37) CYP3A4ALDH1A1KDM4ENPC1MAPT
SCHEMBL12059503 0.74 CYP3A4 (0.46) CYP3A4TGFBR1DHODHMETAP2BRD4
SCHEMBL6922064 0.74 CYP3A4 (0.46) CYP3A4TGFBR1DHODHMETAP2BRD4
SCHEMBL6920827 0.74 CYP3A4 (0.48) CYP3A4TGFBR1DHODHMETAP2GABRG2
SCHEMBL6922265 0.74 CYP3A4 (0.46) CYP3A4TGFBR1DHODHMETAP2GABRG2
SCHEMBL6921554 0.73 CYP3A4 (0.46) CYP3A4TGFBR1DHODHMETAP2BRD4
SCHEMBL14240292 0.73 CYP3A4 (0.36) CYP3A4TGFBR1METAP2PRMT5WDR77
SCHEMBL12059505 0.73 CYP3A4 (0.47) CYP3A4TGFBR1DHODHMETAP2BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof SUNOVION PHARMACEUTICALS INC. (US) 2011-12-29 US disclosed
WO-2011075699-A2 COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof GRM5, GRM2, GRM1 CYP3A4 4447/4885TGFBR1 3543/4885DHODH 2339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.